

***Fiscal Year 2014 Breast Cancer Research Program
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Era of Hope Scholar Award Go to: <ul style="list-style-type: none"> Program Announcement General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-14-BCRP-EOHS	<p>Must be an independent, non-mentored investigator within 6 years of his/her last training position (e.g., postdoctoral fellowship, medical residency, clinical fellowship) as of the application submission deadline.</p>	<ul style="list-style-type: none"> Supports exceptionally talented, creative early-career scientists who have demonstrated that they are the “best and brightest” in their fields. Principal Investigators (PIs) should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention. PIs should exhibit strong potential for leadership in the breast cancer community. PIs must include breast cancer advocates on their research team. 	<ul style="list-style-type: none"> The maximum period of performance is 5 years. The maximum allowable funding for the entire period of performance is \$2.5 million (M) in direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. 	<p>Pre-Application (Letter of Intent): August 1, 2014 5:00 p.m. Eastern time (ET)</p> <p>Confidential Letters of Recommendation Submission Deadline: August 15, 2014 5:00 ET</p> <p>Application: August 15, 2014 11:59 p.m. ET</p>
Innovator Award Go to: <ul style="list-style-type: none"> Program Announcement General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-14-BCRP-INNOV	<p>Must be an Associate Professor or above (or equivalent).</p>	<ul style="list-style-type: none"> Supports visionary individuals who have demonstrated creativity, innovative work, and leadership in any field. Provides opportunity to pursue novel, visionary, high-risk ideas that will accelerate progress toward ending breast cancer. PIs must include breast cancer advocates on their research team. <i>Nomination is required; self-nominations are accepted; application submission is by invitation only.</i> 	<ul style="list-style-type: none"> The maximum period of performance is 5 years. The maximum allowable funding for the entire period of performance is \$5M in direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. 	<p>Pre-Application (Nomination): May 14, 2014 5:00 p.m. ET</p> <p>Confidential Letters of Recommendation Submission Deadline: August 15, 2014 5:00 ET</p> <p>Invited Application: August 15, 2014 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Breakthrough Award Levels 1 and 2</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-14-BCRP-BREAKTHROUGH12</p>	<ul style="list-style-type: none"> • Investigators at all academic levels (or equivalent) are eligible. • Postdoctoral fellows are eligible and encouraged to apply; additional applications components are required. • Each PI may submit only one application as a single PI or Initiating PI. 	<ul style="list-style-type: none"> • Supports promising research that has the potential to lead to or make breakthroughs in breast cancer. • Potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement. • Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application. • It is the responsibility of the PI to select the funding level that is most appropriate for the research proposed. • Submission of a Letter of Intent is required prior to full application submission. • Consumer advocate involvement is encouraged, but not required. • Clinical trials are not allowed. 	<p>Applications may be submitted under one of the following funding levels:</p> <p>Funding Level 1:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$350,000 in direct costs. • The maximum period of performance is 3 years. <p>Funding Level 2:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$700,000 in direct costs. • The maximum period of performance is 3 years. <p>Both Funding Levels:</p> <ul style="list-style-type: none"> • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. 	<p>Pre-Application (Letter of Intent):</p> <p>May 14, 2014 5:00 p.m. ET</p> <p>Application:</p> <p>May, 28 2014 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Breakthrough Award Levels 3 and 4</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-14-BCRP-BREAKTHROUGH34</p>	<ul style="list-style-type: none"> • Independent investigators at all academic levels (or equivalent) are eligible. • Each PI may submit only one application as a single PI or Initiating PI. 	<ul style="list-style-type: none"> • Supports promising research that has the potential to lead to or make breakthroughs in breast cancer. • Potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement. • Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application. • It is the responsibility of the PI to select the funding level that is most appropriate for the research proposed. • Submission of a preproposal is required; <i>application submission is by invitation only</i>. • Clinical trials are allowed. • Applicants are required to include breast cancer advocates on their research team. 	<p>Applications may be submitted under one of the following funding levels:</p> <p>Funding Level 3:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$2.5M in direct costs. • The maximum period of performance is 5 years. <p>Funding Level 4:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$10M in direct costs. • The maximum period of performance is 5 years. <p>Both Funding Levels:</p> <ul style="list-style-type: none"> • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. 	<p>Pre-Application (Preproposal): May 14, 2014 5:00 p.m. ET</p> <p>Invited Application: August 15, 2014 11:59 p.m. ET</p>